Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan and Sumatriptan Coadministration Study
NCT03076970Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lasmiditan in migraine (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change From Pre-dose to 24 Hours in Vital Signs: Systolic Blood Pressure, Change From Pre-dose to 24 Hours in Vital Signs: Diastolic Blood Pressure and 11 more. Started Mar 2017; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03076970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03076970.